Table 2 Clinicopathologic characteristics according to 3 molecular subtypes.
From: Identifying molecular subtypes related to clinicopathologic factors in pancreatic cancer
| Â | Subtype 1 (n = 43) | Subtype 2 (n = 45) | Subtype 3 (n = 8) | P-value |
|---|---|---|---|---|
Age (mean ± SD) | 66.3 ± 8.1 | 64.2 ± 10.3 | 64.8 ± 7.4 | 0.570 |
Male gender | 22 (51.2%) | 20 (44.4%) | 5 (62.5%) | 0.585 |
Tumor size (cm) | 3.0 ± 1.0 | 3.4 ± 1.1 | 3.6 ± 0.8 | 0.073 |
R status | Â | Â | Â | 0.029 |
  R0 | 39 (90.7%) | 31 (68.9%) | 6 (75.0%) |  |
  R1, R2 | 4 (9.3%) | 14 (31.1%) | 2 (25.0%) |  |
AJCC Stage | Â | Â | Â | 0.304 |
  Stage IIA | 19 (44.2%) | 21 (46.7%) | 1 (12.5%) |  |
  Stage IIB | 21 (48.8%) | 22 (48.9%) | 7 (87.5%) |  |
Histologic differentiation | Â | Â | Â | 0.417 |
  Well differentiated | 1 (2.3%) | 1 (2.2%) | 1 (12.5%) |  |
  Moderately differentiated | 39 (90.7%) | 38 (84.4%) | 7 (87.5%) |  |
  Poorly differentiated | 3 (7.0%) | 6 (13.3%) | 0 |  |
Perineural invasion | 35 (81.4%) | 40 (88.9%) | 8 (100%) | 0.298 |
Endolymphatic invasion | 17 (39.5%) | 18 (40.0%) | 4 (50.0%) | 0.690 |
Endovenous invasion | 9 (20.9%) | 16 (35.6%) | 0 | 0.070 |
Adjuvant chemotherapy | 37 (86.0%) | 43 (95.6%) | 7 (87.5%) | 0.215 |
  Gemcitabine | 21 (48.8%) | 30 (66.7%) | 5 (62.5%) | 0.267 |
  5-FU | 10 (23.3%) | 10 (22.2%) | 1 (12.5%) | 0.936 |
  Unknown | 6 (14.0%) | 3 (6.7%) | 1 (12.5%) |  |
Recurrence | 21 (48.8%) | 32 (71.1%) | 5 (62.5%) | 0.091 |
  Local | 10 (23.3%) | 11 (24.4%) | 2 (25.0%) | 1.0 |
  Distant | 17 (39.5%) | 30 (66.7%) | 3 (37.5%) | 0.022 |